Rhythm Pharmaceuticals (RYTM) EPS (Weighted Average and Diluted) (2020 - 2025)
Historic EPS (Weighted Average and Diluted) for Rhythm Pharmaceuticals (RYTM) over the last 6 years, with Q3 2025 value amounting to -$0.82.
- Rhythm Pharmaceuticals' EPS (Weighted Average and Diluted) fell 1232.88% to -$0.82 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.1, marking a year-over-year increase of 2840.65%. This contributed to the annual value of -$4.34 for FY2024, which is 3545.86% down from last year.
- Latest data reveals that Rhythm Pharmaceuticals reported EPS (Weighted Average and Diluted) of -$0.82 as of Q3 2025, which was down 1232.88% from -$0.75 recorded in Q2 2025.
- Over the past 5 years, Rhythm Pharmaceuticals' EPS (Weighted Average and Diluted) peaked at $0.9 during Q1 2021, and registered a low of -$2.35 during Q1 2024.
- Moreover, its 5-year median value for EPS (Weighted Average and Diluted) was -$0.79 (2022), whereas its average is -$0.79.
- In the last 5 years, Rhythm Pharmaceuticals' EPS (Weighted Average and Diluted) soared by 21538.46% in 2021 and then plummeted by 21666.67% in 2022.
- Quarter analysis of 5 years shows Rhythm Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$1.03 in 2021, then rose by 20.48% to -$0.82 in 2022, then increased by 11.46% to -$0.72 in 2023, then decreased by 1.36% to -$0.73 in 2024, then fell by 12.07% to -$0.82 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$0.82 for Q3 2025, versus -$0.75 for Q2 2025 and -$0.81 for Q1 2025.